Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02367313 · ClinicalTrials.gov registry record · Phase 2
A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection
A Phase 2 study of Asthma, sponsored by Biota Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 455
- Enrollment target
- 20
- Study locations
NCT02367313: Completed Phase 2 study of Asthma, sponsored by Biota Pharmaceuticals.
NCT02367313 is a Phase 2 study of Asthma that has completed, run by Biota Pharmaceuticals. The registered enrollment target is 455 participants, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (71% lower). The trial reports 20 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02367313, a Phase 2 study of Asthma, has completed, sponsored by Biota Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 455 participants
- Enrollment target
- 20
- Study locations
Study Summary
This Phase 2 protocol is designed to compare two dose levels of Vapendavir versus placebo. The objectives are to obtain safety and efficacy data in moderate to severe asthmatic patients, aged 18 to 75 years at risk of loss of asthma control due to presumptive Human Rhinovirus infection.
Primary Outcome
Least Square (LS) mean change from baseline (Day 1) to Study Day 14 in ACQ-6 total score
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Vapendavir
Study Locations (20)
California
- Biota Investigational site - Bakersfield
- Biota Investigational site - Los Angeles
- Biota Investigational site - Orange
- Biota Investigational Site - San Jose
- Biota Investigational site - Stockton
Florida
- Biota Investigational site - Hialeah
- Biota Investigational site - New Port Richey
- Biota Investigational site - Oviedo
- Biota Investigation site - Palmetto Bay
- Biota Investigational site - Tallahassee
Colorado
- Biota Investigational site - Centennial
- Biota Investigational site - Denver
Alabama
- Biota Investigational site - Birmingham
Arizona
- Biota Investigational site - Flagstaff
Idaho
- Biota Investigational site - Twin Falls
Maryland
- Biota Investigational site - Baltimore
Missouri
- Biota Investigational site - St Louis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 455 participants |
| Start Date | 2015-02 |
| Est. Completion | 2016-12 |
| Phase | Phase 2 |
What the finished NCT02367313 record still lists
NCT02367313 is an interventional study that assigns participants to a tested intervention. The registered 455 participants enrollment target is mid-sized for trials with a published cap, below the 1,562-participant average among 374 other Asthma trials with a reported enrollment target (71% lower).
The record links to 1 condition, with Asthma appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT02367313 names 20 study sites across 11 states, led by California, Florida, Colorado.
Frequently Asked Questions
What is clinical trial NCT02367313 about?
NCT02367313 is a clinical study titled "A Phase 2 Study of Vapendavir in Asthmatic Adults With Symptomatic Human Rhinovirus Infection". This Phase 2 protocol is designed to compare two dose levels of Vapendavir versus placebo. The objectives are to obtain safety and efficacy data in moderate to severe asthmatic patients, aged 18 to 75 years at risk of loss of asthma control due to presumptive Human Rhinovirus infection.
What is the current status of trial NCT02367313?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 455 participants. The study started on 2015-02. Estimated completion is 2016-12.
What conditions does trial NCT02367313 study?
This clinical trial studies the following conditions: Asthma.
What interventions are being tested in trial NCT02367313?
The interventions under investigation include: Placebo (DRUG), Vapendavir (DRUG).
Who is sponsoring clinical trial NCT02367313?
This trial is sponsored by Biota Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02367313 being conducted?
This trial has 20 study locations across Alabama, Arizona, California, Colorado, Florida. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Asthma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02367313's enrollment target sits among peer trials
455 81st of 374 higher than 294 of 374 other Asthma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Asthma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Escitalopram in Asthma Patients With Frequent Exacerbation
RECRUITING · Phase 2
-
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
RECRUITING · Phase 2
-
Study of Lunsekimig (SAR443765) Compared With Placebo in Adults With High-risk Asthma
RECRUITING · Phase 2
-
ENV-294 for Moderate-to-Severe Asthma: A 12-Week Study in Adults
RECRUITING · Phase 2
-
A Study to Evaluate Brenipatide Compared With Placebo in Adult Participants With Uncontrolled Moderate to Severe Asthma
RECRUITING · Phase 2
-
Supplementing L-citrulline to Overweight Late Asthma oNset Phenotypes
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT05541016 · 455 participants · Phase 2
De-Escalated Adjuvant and Definitive Radiation Therapy Informed by DART 2.0 ctHPV-DNA
- NCT06079346 · 455 participants · Phase 2
A Study of OT-101 With mFOLFIRINOX in Patients With Advanced and Unresectable or Metastatic Pancreatic Cancer
- NCT06504446 · 455 participants · Phase 2
Study to Assess the Efficacy, Safety, and Tolerability of NOC-110 in Adults With Refractory or Unexplained Chronic Cough
- NCT06725030 · 455 participants
A Post-market, Real-world Experience: Expanding Access to Care by Incorporating the Symani® Surgical System and Enabling Surgeons
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia